BioInformant

Your Global Leader in Stem Cell Market Research

Home » Stem Cell News » Page 28

Stem Cell News

BioInformant's coverage of stem cell news includes iPS cells, mesenchymal stem cells, hematopoietic stem cells, neural stem cells and more.

As the first and only market research firm to specialize in stem cell news, BioInformant research has been cited by the Wall Street Journal, Xconomy, AABB, and Vogue Magazine.

Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry news.

Immunofluorescent Staining Within Hours, Not Days

By Leave a Comment

AMSBIO has launched CellO-IF – an all-in-one immunofluorescent staining reagent kit designed to accelerate the labelling organoids and spheroids directly in hydrogels or extracellular matrices, while preserving delicate structures and cellular integrity.

Immunofluorescence (IF) allows detection and localization of antigens in diverse types of tissues in various cell preparations. The technique provides excellent sensitivity and amplification of signal by comparison to immunohistochemistry. However, traditional IF staining is a labor intensive, multi-step process. CellO-IF revolutionizes this by streamlining the procedure. [Read more…]

South Korea’s SK bioscience Completes Acquisition of Germany’s CDMO IDT Biologika

By Leave a Comment

SK bioscience completed the acquisition of German CDMO company IDT Biologika with over a century of history that enables immediate expansion in revenue and infrastructure.
The company aims to double sales of IDT Biologika by 2028 through new business projects and operational efficiency.
The company will invest in high-growth businesses such as stage cell and gene therapy (CGT) and recombinant vaccine.
SK bioscience will accelerate its global push based on the complementary capabilities of both companies.

[Read more…]

Dominance of Cellular Dynamics International (CDI) within iPSC Marketplace

By Leave a Comment

Cellular Dynamics International (CDI), a FUJIFILM company, is the largest provider of induced pluripotent stem cell (iPSC) products worldwide. iPSCs are a type of laboratory made stem cell that has significant potential for use within regenerative medicine.

In theory, iPSCs have the potential to treat a wide range of diseases, including diabetes, heart diseases, autoimmune diseases, neural decline and more. iPSCs are also being widely implemented for use in drug development and discovery, as well as toxicology screening and personalized medicine.

In this article:

Cellular Dynamics International and iPSC Therapy

Since September 2016, Cellular Dynamics International (CDI) has been divided into two business units, a Therapeutics Business Unit and a Life Science business unit. CDI’s Therapeutics business unit is focused on developing induced pluripotent stem cell (iPSC) based therapies for ocular, cardiac, neural and oncology applications. In contrast, CDI’s Life Science business unit is focused on developing the research products side of the business.

iPSC Market Competitors

In addition to CDI, there are many other companies and organizations that are involved with the development of induced pluripotent stem cell (iPSC) therapies, including but not limited to:

  • Ocata Therapeutics
  • RIKEN
  • Kyoto University and CiRA
  • Fate Therapeutics
  • Megakaryon Corporation
  • Cynata Therapeutics

There are also a number of companies specializing in iPSC product development, including:

  • Allele Biotechnology
  • ALSTEM Bio
  • Applied Biological Materials (ABM)
  • Applied StemCell
  • Axol Bioscience
  • BrainXell
  • Cell Applications
  • Cellular Dynamics International (a Fujifilm Company)
  • EMD Millipore
  • Minerva Biotechnologies
  • Ncardia (formed through merger of Axiogenesis and Pluriomics)
  • Neucyte
  • Pluricell Biotech
  • REPROCELL
  • Sigma Aldrich (provides 350 iPSC lines through partnership with EBiSC)
  • STEMCELL Technologies
  • Stemgent (iPS Cell Business Unit owned by ReproCELL)
  • Takara Bio
  • Tempo Bioscience
  • Thermo Fisher Scientific
  • xCell Sciences
  • And others

Fujifilm Cellular Dynamics Inc.

Cellular Dynamics International is one of the most important market participants in the iPSC sector, because of its dominance in both iPSC therapies and life science tools.

[Read more…]

RxCell Inc. Granted U.S. Patent for iPSC-based Cell Therapy

By Leave a Comment

PARK CITY, Utah, September 19, 2024 – RxCell Inc. is pleased to announce the issuance of U.S. Patent 11,946,069 entitled “Method for Generating Multiple Cellular Products from Single Pluripotent Cell Source”, a significant advancement in the field of regenerative medicine. This patent, granted on April 2, 2024, provides RxCell with exclusive rights to induced pluripotent stem cell (iPSC)-derived cells for therapy across a broad spectrum of diseases. [Read more…]

GC Therapeutics Launches with $75M and Star-Studded Leadership to Scale Allogeneic iPSC-Derived Cell Therapies

By Leave a Comment

  • TFome could revolutionize cell therapy by delivering off-the-shelf iPSC-based medicines at a pace up to 100X more rapidly than conventional methods via a single-step process with improved potency, efficiency, quality and cost
  • TFome™ is the world’s first “plug-and-play” iPSC cellular programming platform.
  • The company raised $75M from Cormorant Asset Management, Mubadala Capital, a16z Bio + Health, Medical Excellence Capital, Cercano Management, & Pear VC

[Read more…]

Shopping cart0
There are no products in the cart!
Continue shopping
0